Ashley Gomm

Ashley Gomm

Auto-generated profile, based on publicly available information

Ashley Gomm

Genetics and Aging Research Unit, McCance Center for Brain Health, Massachusetts General Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2022 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
PBPing Bai
Ping Bai
PMPrasenjit Mondal
Prasenjit Mondal
FBFrederick A. Bagdasarian
Frederick A. Bagdasarian
NRNisha Rani
Nisha Rani
YLYan Liu
Yan Liu
CWChangning Wang
Changning Wang
Although the epigenetic regulatory protein histone deacetylase 6 (HDAC6) has been recently implicated in the etiology of Alzheimer's disease (AD), little is known about the role of HDAC6 in the etiopathogenesis of AD and whether HDAC6 can be a potential therapeutic target for AD. Here, we performed positron emission tomography (PET) imaging in combination with histopathological analysis to better understand the underlying pathomechanisms of HDAC6 in AD. We first developed [18F]PB118 which was demonstrated as a valid HDAC6 radioligand with excellent brain penetration and high specificity to HDAC6. PET studies of [18F]PB118 in 5xFAD mice showed significantly increased radioactivity in the brain compared to WT animals, with more pronounced changes identified in the cortex and hippocampus. The translatability of this radiotracer for AD in a potential human use was supported by additional studies, including similar uptake profiles in non-human primates, an increase of HDAC6 in AD-related human postmortem hippocampal tissues by Western blotting protein analysis, and our ex vivo histopathological analysis of HDAC6 in postmortem brain tissues of our animals. Collectively, our findings show that HDAC6 may lead to AD by mechanisms that tend to affect brain regions particularly susceptible to AD through an association with amyloid pathology.

21 November 2023 in Advanced Science
Verified
Journal Article
Open access
PMPrasenjit Mondal
Prasenjit Mondal
PBPing Bai
Ping Bai
AGAshley Gomm
Ashley Gomm
GBGrisilda Bakiasi
Grisilda Bakiasi
CLChih‐Chung Jerry Lin
Chih‐Chung Jerry Lin
Can ZhangCan Zhang
Can Zhang
Histone deacetylase 6 (HDAC6) is one of the key histone deacetylases (HDACs) that regulates various cellular functions including clearance of misfolded protein and immunological responses. Considerable evidence suggests that HDAC6 is closely related to amyloid and tau pathology, the two primary hallmarks of Alzheimer's disease (AD). It is still unclear whether HDAC6 expression changes with amyloid deposition in AD during disease progression or HDAC6 may be regulating amyloid phagocytosis or neuroinflammation or other neuropathological changes in AD. In this work, the pathological accumulation of HDAC6 in AD brains over age as well as the relationship of its regulatory activity ‐ with amyloid pathogenesis and pathophysiological alterations is aimed to be enlightened using the newly developed HDAC6 inhibitor (HDAC6i) PB118 in microglia BV2 cell and 3D‐AD human neural culture model. Results suggest that the structure‐based rational design led to biologically compelling HDAC6i PB118 with multiple mechanisms that clear Aβ deposits by upregulating phagocytosis, improve tubulin/microtubule network by enhancing acetyl α‐tubulin levels, regulate different cytokines and chemokines responsible for inflammation, and significantly reduce phospho‐tau (p‐tau) levels associated with AD. These findings indicate that HDAC6 plays key roles in the pathophysiology of AD and potentially serves as a suitable pharmacological target through chemical biology‐based drug discovery in AD.

4 July 2025 in Science Advances
Verified
Journal Article
Open access
SMSean J. Miller
Sean J. Miller
RDRahul M. Dhodapkar
Rahul M. Dhodapkar
HSHande Eda Sutova
Hande Eda Sutova
YXYao Xue
Yao Xue
SLSeunghoon Lee
Seunghoon Lee
BHBrian P. Hafler
Brian P. Hafler
While the etiology of Alzheimer’s disease remains unknown, there is growing support for the amyloid-β antimicrobial hypothesis. Amyloid-β, the main component of amyloid plaques in Alzheimer’s disease, has been shown to be generated in the presence of microbes. Entrapment of microbes by aggregated amyloid-β may serve as an innate immune response to pathogenic infections. To understand the association of amyloid-β plaques and pathogenic infections in the central nervous system, we obtained viable short-interval postmortem human retinal tissue and generated human retinal organoids that contain electrophysiologically active neurons. Here, we demonstrate that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces amyloid-β extracellular protein aggregates in human retinal explants and retinal organoids. Last, pharmacological inhibition of neuropilin-1 resulted in reduced amyloid-β deposition in human retinal explants treated with SARS-CoV-2 Spike 1 protein. These results suggest that Spike 1 protein, during infection with SARS-CoV-2, can induce amyloid-β aggregation, which may be associated with the neurological symptoms experienced in COVID-19.

12 April 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PBPing Bai
Ping Bai
FBFrederick A. Bagdasarian
Frederick A. Bagdasarian
YXYulong Xu
Yulong Xu
YWYanli Wang
Yanli Wang
YWYongle Wang
Yongle Wang
CWChangning Wang
Changning Wang